IFNG and breast carcinoma: Nie and the coworkers combined their antagonistic anti-TNFR2 antibody, TR75-54.7, with an anti-CD25 antibody as therapy in murine colorectal and breast cancer models; they found significantly fewer TNFR2+ Tregs and more infiltrating IFN-γ+ Teffs, and remarkably decreased tumors [72].